PlainRecalls
FDA Drug Moderate Class II Ongoing

Atomoxetine Capsules, USP, 25 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-267-30.

Reported: February 26, 2025 Initiated: January 29, 2025 #D-0233-2025

Product Description

Atomoxetine Capsules, USP, 25 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-267-30.

Reason for Recall

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Details

Units Affected
175,920 bottles
Distribution
Nationwide within the U.S
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Atomoxetine Capsules, USP, 25 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-267-30.. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 175,920 bottles.
Why was this product recalled?
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 26, 2025. Severity: Moderate. Recall number: D-0233-2025.